AN2 Therapeutics Inc (ANTX) — Cash Flow-to-Debt Ratio
AN2 Therapeutics Inc (ANTX) has a Cash Flow-to-Debt Ratio of -0.59x as of December 2025, meaning its operating cash flow of $-5.24 Million could theoretically repay -1% of its total liabilities ($8.89 Million) in one year. See ANTX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AN2 Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for AN2 Therapeutics Inc across 7 annual periods. Also explore net asset growth rate of AN2 Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AN2 Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for AN2 Therapeutics Inc. For market capitalisation and broader financial context, see how much is AN2 Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.36x | $-29.83 Million | $8.89 Million | ▲ +30.2% |
| 2024 | -4.81x | $-49.26 Million | $10.24 Million | ▼ -26.8% |
| 2023 | -3.79x | $-53.29 Million | $14.04 Million | ▲ +18.5% |
| 2022 | -4.66x | $-33.46 Million | $7.19 Million | ▲ +22.5% |
| 2021 | -6.01x | $-20.48 Million | $3.41 Million | ▼ -66.2% |
| 2020 | -3.62x | $-5.36 Million | $1.48 Million | ▼ -29.1% |
| 2019 | -2.80x | $-2.49 Million | $887.00K | — |